Sartorius, LFB Biomanufacturing Expand Collaboration

Editor’s take: The alliance combines Sartorius’ cell line development with LFB Biomanufacturing’s process development and GMP manufacturing capabilities into an end-to-end offering for biologics clients.

Sartorius and LFB Biomanufacturing have expanded their collaboration with the aim of offering biopharmaceutical clients a comprehensive CLD to first batch of GMP drug substance service to help simplify and accelerate the path to the clinic. 

Building on their collaboration launched in March 2024, this step will combine Sartorius expertise in CLD and master cell bank manufacturing with capabilities from LFB’s upstream and downstream process development, analytical development and testing, and GMP drug substance manufacturing. The collaboration enables each company to gain access to each other’s respective platforms and technologies to offer a single path to the clinic.

“Our clients are at the center of this collaboration,” said Stefan Northoff, Head of Cell Line, Media, and Testing Solutions at Sartorius. “By collaborating with LFB Biomanufacturing, we combine our cutting-edge CLD technology, including our recently launched genetically engineered host cell line, with expertise from LFB in manufacturing, to help our clients achieve success as they take their therapeutics seamlessly to the clinic.”

“Through the strengthened collaboration between Sartorius and LFB BIOMANUFACTURING, our clients will gain access to a powerful combination of expertise spanning CLD, process optimization, and manufacturing,” said Herbert Guedegbe, Managing Director of LFB Biomanufacturing. “This will enable our clients to move their innovative drug development programs forward with greater confidence and speed while improving patient outcomes.”

LFB is a CDMO with extensive experience developing therapeutic proteins, including monoclonal antibodies, Fc-fusions, bispecifics, and other complex biologics. Sartorius brings more than 15 years of commercial CLD experience, with more than 85 programs advancing into clinical development and over 10 achieving market approval.